Enovis Corporation is a medical technology company. It is focused on developing clinically differentiated solutions by manufacturing and distributing high-quality medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. It operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative diseases. The Prevention & Recovery products are marketed under several brand names, such as DJO. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. It also operates a Enovis Growth eXcellence business system (EGX).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 31.68% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.25B.
Overvalued
The company’s latest PE is -1.01, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 68.97M shares, decreasing 8.93% quarter-over-quarter.
Held by Mason Hawkins
Star Investor Mason Hawkins holds 43.70K shares of this stock.